Features

People don't call in sick to extend their weekends, and parents of young children don't take more sick leave. So what is the main factor?

Israeli venture capitalist Eden Shochat tells the ‘science fiction’ story and inspired bet behind the Israeli startup that has become Apple’s second biggest-ever acquisition.

As the control battle for the aesthetic medicine company heats up, co-founder and CEO Moshe Mizrahy blasts activist investors and backs the employees.

Aviad Maizels has pulled off the unique trick of selling two companies to Apple but this time with much greater financial success.

To overcome the difficulties of holding Bitcoin in Israel, ZOOZ CEO Jordan Fried recommends buying his company’s stock.

The ambition of executing so many major projects all at once, headed by the Metro, is not matched by the availability of resources.

Leader of the Opposition Yair Lapid claims that the emigrants in 2025 were all permanent Israeli residents. The statistics don't bear him out.

“Globes” examines the urban development challenges facing small towns that will more than double in size in the coming years.

Or Yehuda-based Elsight is traded in Australia and has seen its share price soar 1,000% thanks to the surge in the drones market.

President Trump astonished Israelis by claiming that Iron Dome is "our technology." So who really takes the credit for the air defense system's success?

American-Iranian investor Amir Heshmatpour made his fortune in US biotech companies. He’s now in Israel with NeOnc, developer of a nasally administered brain cancer drug.

At 64, in the midst of giving evidence in the Netanyahu corruption trial, former Walla! CEO Ilan Yeshua cofounded Seraphic Security, acquired this week by Crowdstrike.

INSS Senior Researcher Prof. Kobi Michael tells “Globes” about potential scenarios in Iran and says Israel will only intervene if asked to do so by the US.

A panel from Lipa & Co., Greenberg Traurig and Valley Bank examined the expansion of defense-tech companies into the US, exploring risks and focusing on opportunities and strategic considerations.

Prof. Michael Hayden left Teva taking two products that it had begun developing. One became an almost $3.5 billion exit last September.

Nvidia SVP networking Gilad Shainer tells “Globes” that it would not be possible for the company to power the new AI models without the communication chips developed in Israel.